Skip to main content
Head Researcher
Neurogénesis y epileptogénesis
Terapia génica síndrome de Dravet
Terapia celular síndrome de Dravet
Nanopartículas Inorgánicas
Dravet Zebrafish
Estimulación transcraneal magnética
Medicina de precisión y síndrome de Dravet: modelo Drosophila
Drug Discovery-Buenos Aires (Argentina)
Cannabinoides y epilepsia
Research groups
Anti-oxidant/anti-inflamatory nanoparticles to protect the brain from excess electrophysiology and to mitigate damage post-crisis (Inorganic Nanoparticles)
Cell Therapy with GABAergic interneuron precursors for Early Infantil Epileptic Encephalopathies (S. Dravet, S. West y S. Stxbp1)

(Cell-based Therapy for Neuropathologies Lab)

Characterization of the didys552 zebrafish mutant line (mutation in snc1lab gene) and set up of an efficacy drug screening assay using reference compounds (Dravet unit in Biobide)
Creation of a therapeutic drug monitoring (TDM) unit for the optimization of the Dravet syndrome pharmacological therapy (Laboratory of Bioactive Research and Development (LIDeB))
Design, synthesis and pharmacological evaluation of new neuroprotective agents oriented to the tratment of Dravet syndrome

(Laboratory of Bioactive Research and Development (LIDeB))

Efecto de campos magnéticos estáticos de intensidad moderada en modelos de epilepsia y síndrome de Dravet

(Neurocom-Neurofisología experimental)

Intrinsic neuronal excitability and spontaneous 1 activity underlie cortical abnormalities upon Nr2f1/COUP-TFI deficiency

(Neural Plasticity Group)

Investigating Epilepsy by Super-resolution Imaging of Synapses and the Extracellular Space in Live Brain Tissue

(Laboratory of Neuronal Excitability)

Precision Medicine in Dravet Syndrome

(Developmental Biology and Disease Models)

Reactive Neurogenesis and Gliogenesis in a Dravet Syndrome Mouse Model

(The Neural Stem Cell and Neurogenesis Lab)

The effect of beta-caryophyllene treatment in a murine model of Dravet syndrome

(Cannabinoides y síndrome de Dravet)

The endocannabinoid system study in Dravet syndrome

(Cannabinoids and Dravet syndrome)

The Apoyodravet Association (AD) central pillars are social innovation, patient-oriented technology and the promotion of research in the service of disease modification.

If you want to stay updated on the INDRE international research network please...